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Non-Prescription Medicinal Products 
Containing Codeine: Guidance for 
Pharmacists on Safe Supply to Patients
Pharmaceutical	Society	of	Ireland	
Version	4	April	2019
Updates	made	following	the	enactment	of	the	Misuse	of	Drugs	Regulations	20171		
(which	replaced	the	Misuse	of	Drugs	Regulations	1988	(as	amended)2	are	highlighted	in	grey).
1 Please note: where the Misuse of Drugs Regulations are cited in other legislation please refer to Schedule 9 
‘Provisions of revoked Misuse of Drugs Regulations 1988 and corresponding provisions in these Regulations’ of the 
Misuse of Drugs Regulations 2017.
2 Misuse of Drugs (Safe Custody) Regulations 1982, as amended, remain applicable.
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3 Codeine-containing analgesics. HPRA (formally the IMB) 
Drug Safety Newsletter. Issue No.19, June 2004.   
1. Introduction
The overall purpose of this guidance is to 
improve patient safety in the use of non-
prescription medicinal products containing 
codeine (hereafter called ‘codeine medicine’)  
by ensuring the safe supply of codeine 
medicines by pharmacists. This guidance is 
intended to assist pharmacists in meeting 
their legal and professional responsibilities 
when supplying these medicines to patients 
and when providing advice, guidance and 
assistance in respect of the use of these 
medicines. It is also intended to assist 
superintendent and supervising pharmacists  
in securing compliance with relevant legislative 
and professional obligations under the 
Pharmacy Act 2007, including the Regulation  
of Retail Pharmacy Businesses Regulations 
2008 (S.I. No. 488 of 2008). 
The safety concerns around the misuse of non-
prescription medicinal products containing 
codeine are well established. Consumption of 
quantities of these medicines in excess of the 
recommended dose, or over a prolonged period 
of time, may cause tolerance and dependence, 
as well as the risk of other adverse effects. 
Furthermore, the consumption of excessive 
quantities of ‘combination products’, i.e. those 
containing codeine and another analgesic 
such as paracetamol, aspirin or ibuprofen, also 
increases the risk of harm from these other 
medicinal products. This risk applies to both 
short and long-term use.
Recent publications have highlighted the 
ongoing concerns regarding these medicinal 
products in other jurisdictions. This includes 
publications by the UK’s Medicines and 
Healthcare products Regulatory Agency 
(MHRA), the Pharmaceutical Society 
of Northern Ireland (PSNI), the Royal 
Pharmaceutical Society of Great Britain 
(RPSGB), the Therapeutic Goods Administration 
(TGA) in Australia and pharmacy regulatory 
authorities in Canada.
2. Codeine
Codeine phosphate is a mild to moderate 
opioid (narcotic) analgesic and has weak 
cough suppressant activity3. Codeine, due to 
its potential for misuse, is a controlled drug 
under the Misuse of Drugs Acts 1977 and 
1984. Low dose preparations are regulated as a 
Schedule 5 controlled drug. As an analgesic, it 
is most often used in combination with other 
analgesics such as paracetamol or ibuprofen 
and is currently authorised in Ireland in such 
non-prescription products for pain relief. It 
is also available in single ingredient, non-
prescription products, as a cough suppressant. 
These authorised products are available 
without a prescription through retail pharmacy 
businesses (pharmacies) only.
The Pharmacy Act 2007 and the Regulation of 
Retail Pharmacy Businesses Regulations 2008 
(S.I. No. 488 of 2008) require that all medicines 
supplied through a retail pharmacy business 
must be supplied by or under the personal 
supervision of a pharmacist (regulation 5(1)
(d)) and that all non-prescription medicines 
supplied must be the subject of appropriate 
counselling (regulation 10). In addition, 
because of the particular characteristics of 
those medicines containing controlled drugs 
(i.e. codeine), further restrictions are imposed 
which require that those medicinal products 
would not be accessible to the public for 
self-selection (regulation 5(1)(e)). Therefore, 
self-selection of medicinal products containing 
controlled drugs (i.e. CD5 medicines) without 
the provision of appropriate supervision, 
professional support, advice and information 
by the pharmacist is not appropriate.
Codeine medicines should only be supplied 
when the pharmacist deems such a supply 
is necessary and only when a non-opioid 
analgesic, e.g. paracetamol, aspirin or 
ibuprofen, has not proven sufficient to relieve 
the patient’s symptoms. If recommended, 
codeine medicines should be used for the 
shortest time possible and for no longer than 
three days without medical supervision.
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Codeine is a narcotic analgesic and it is 
important that the recommended dose 
should not be exceeded in any 24-hour period. 
Consumption of quantities in excess of the 
recommended dose, or consumption over a 
prolonged period of time, may cause tolerance 
and dependence and may result in withdrawal 
symptoms such as restlessness and irritability 
upon cessation of the medicine3. If a patient 
needs to use codeine medicines for periods 
longer than the three days, it is considered 
important that they consult their doctor to 
investigate unresolved symptoms and the  
most appropriate treatment.
3. Legal 
Considerations
3.1 Code of Conduct  
for Pharmacists
The first principle of the Code of Conduct 
for pharmacists requires that the practice 
by a pharmacist of his/her profession 
must be directed toward maintaining and 
improving the health, wellbeing, care and 
safety of patients. Pharmacists should use 
their professional skills and competence, 
and specialised knowledge, to encourage the 
rational and proper use of medicines. They may 
be required to use their professional skills in 
decision-making, which may at times come 
into conflict with the demands of the patient.
Pharmacists, in particular superintendent 
and supervising pharmacists, should ensure 
that in whichever areas of practice they 
operate, suitable controls and accountability 
mechanisms are in place, in order to 
appropriately control the supply of all 
medicinal products which are known to have 
the potential for abuse and/or dependency.
3.2 Regulation of Retail 
Pharmacy Businesses 
Regulations 2008  
(S.I. No. 488 of 2008)
These regulations set out the requirements 
that must be complied with by persons 
carrying on retail pharmacy businesses in  
their dealings with medicinal products.
 
3.2.1 Management and Supervision  
of a Retail Pharmacy Business
According to the Regulation of Retail Pharmacy 
Businesses Regulations 2008 (S.I. No. 488 of 
2008) the sale and supply of all medicinal 
products must be by or under the personal 
supervision of a pharmacist.
Regulation 5(1)(d): 
5.(1) The pharmacy owner and the 
superintendent pharmacist shall, inter alia, 
ensure that— 
(d)  the sale or supply of medicinal products, 
including veterinary medicinal products, 
and the preparation, dispensing and 
compounding of prescriptions, including 
veterinary prescriptions, at the premises, 
are carried out by or under the personal 
supervision of a registered pharmacist,
 Furthermore, Regulation 5(1)(e) of 
those Regulations requires that any 
medicinal product which is a Schedule 
5 controlled drug (e.g. non-prescription 
medicinal products containing codeine) 
must not be accessible to the public for 
self-selection.
Regulation 5(1)(e): 
(e)  medicinal products that are subject to 
prescription control under the Medicinal 
Products (Prescription and Control of 
Supply) Regulations 2003 (S.I. No. 540 
of 2003) (as amended) and medicinal 
products that are controlled drugs listed 
in Schedule 5 to the Misuse of Drugs 
Regulations 2017 (S.I. No. 173 of 2017) 
are not accessible to the public for self-
selection.
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4 ‘advertising’, in relation to a medicinal product, includes any form of door to door information, canvassing activity or 
inducement designed to promote the prescription, supply, sale or consumption of medicinal products and including in 
particular—
(a)  the advertising of medicinal products to the general public;
(b)  the advertising of medicinal products to persons qualified to prescribe or supply them;
(c)  visits by medical sales representatives to persons qualified to prescribe medicinal products;
(d)  the supply of samples of medicinal products;
(e)  the provision of inducements to prescribe or supply medicinal products by the gift, offer or promise of any benefit or 
bonus, whether in money or in kind;
(f)  the sponsorship of promotional meetings attended by persons qualified to prescribe or supply medicinal products; and
(g)  the sponsorship of scientific congresses attended by persons qualified to prescribe or supply medicinal products and in 
particular payment of their travelling and accommodation expenses in connection therewith; and cognate words shall 
be construed accordingly;
3.2.2 Counselling in the Supply of 
Medicinal Products other than on  
Foot of a Prescription
Regulation 10 of those Regulations, in 
particular, sets out the role and responsibility 
of pharmacists in the sale and supply of  
non-prescription medicines.
Regulation 10: 
10. A person carrying on a retail pharmacy 
business, the superintendent pharmacist 
and the supervising pharmacist shall 
ensure that, in the course of the sale or 
supply of a medicinal product other than 
on foot of a prescription and prior to such 
sale or supply, a registered pharmacist is 
satisfied that the purchaser or other such 
person is aware of what the appropriate 
use of the medicinal product is and that it 
is being sought for that purpose and, in so 
far as the registered pharmacist is aware, 
the product is not intended for abuse  
and/or misuse.
3.3 Medicinal Products 
(Control of Advertising) 
Regulations 2007  
(S.I. No. 541 of 2007)
Regulation 10 of these Regulations, in relation 
to advertising directed wholly or mainly at 
members of the general public, provides that: 
a person shall not issue an advertisement4 in 
respect of any medicinal product which is a 
controlled drug under section 2 of the Misuse  
of Drugs Act 1977 (No. 12 of 1977).
In addition, Regulation 22(2) of those 
Regulations provides that: a person shall not 
supply a sample of a medicinal product which is 
a controlled drug under section 2 of the Misuse 
of Drugs Act 1977 or which is an antidepressant, 
hypnotic, sedative or tranquilliser.
As a consequence of these provisions, any 
form of advertising of a medicinal product 
that is a controlled drug, irrespective of the 
schedule into which the drug is classified, that 
is directed at the public is prohibited. This 
would include any form of window displays, 
in-pharmacy promotions and promotional 
displays, promotional leaflets and shelf 
stickers.
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4. Guidance
4.1 The Supply of Non-
Prescription Medicines 
Containing Codeine
Codeine medicines are currently authorised 
for the relief of pain in conditions such as 
rheumatic and muscular pain, migraine, 
headache, menstrual pain, toothache, 
backache and for symptoms of the common 
cold and influenza, and the majority are 
available as non-prescription medicines from 
retail pharmacy businesses only5.
• The supply of codeine medicines may 
only be made by or under the personal 
supervision of a pharmacist who would be in 
a position to determine the appropriateness 
of the request. In addition, because of the 
particular characteristics of those medicines 
containing controlled drugs (i.e. codeine), 
further restrictions are imposed which 
require that those products would not be 
accessible to the public for self-selection.
• Every time a codeine medicine is supplied, 
the pharmacist must be satisfied that 
in the exercise of his or her professional 
judgement, the supply of such a medicine 
is the most appropriate treatment available 
at the time and that such supply is in the 
best interest of the patient. It should also 
be taken into account that non-codeine-
containing medicinal products for the same 
indications should be considered as first-line 
treatments, e.g. ibuprofen, paracetamol or 
aspirin6.
• The pharmacist is often the first point of 
contact for a patient and therefore has 
an important role to discharge in the 
correct management of pain. This includes 
providing appropriate advice or medication, 
recognising the need for referral for further 
medical investigation and the need for 
vigilance in relation to the presentation of 
patients with medication overuse headache 
and chronic daily headache.
• Codeine medicines should only be taken 
when the pharmacist considers it necessary 
and for the shortest period considered 
necessary. Combination products with 
ibuprofen and paracetamol recommend that 
the duration of treatment should be for no 
longer than three days. Any requirement 
for more prolonged use should only be 
considered under medical supervision.
• Patients should be advised of the importance 
of adhering to the recommended dosage 
and duration of use. Patients should be 
informed that chronic use and consumption 
of quantities in excess of the recommended 
dose, or for a prolonged period of time, 
may lead to tolerance, psychological and 
physical dependence and may result in 
the development of symptoms such as 
restlessness and irritability upon cessation 
of this medicine3.
• The risks associated with overdose and/or 
prolonged use should be addressed with the 
patient.
• For products which also contain paracetamol 
or ibuprofen, the patient should be informed 
that these medicines have the potential to 
be harmful in overdose quantities or if used 
for a prolonged period of time.
• If patients experience the need to use 
codeine medicines over a prolonged period 
of time (i.e. more than three days) for pain 
relief or relief of another symptom, the 
patient should be referred to a medical 
practitioner who would be able to review 
their symptoms and provide appropriate 
treatment under medical supervision.
• Patients should also be counselled in the 
course of each supply in respect of other 
potential adverse reactions or side effects, 
including nausea, constipation, dizziness 
and drowsiness (which may impair their 
ability to drive safely). They should also be 
counselled, as appropriate, regarding the 
contraindications for use, drug interactions, 
or existing medical conditions, which may 
preclude the use of these medicines. The 
need for safe storage of these medicines 
should also be addressed with patients.
5 Marketing authorisations granted by the Health Products Regulatory Authority. 
6 Pharmacological management of pain in primary care (2): opioids. National Medicines Information Centre. Volume 11, 
Number 6, 2005.
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4.2 Policies and Procedures 
Superintendent pharmacists must ensure that 
the policies in the retail pharmacy business(es) 
under their control adhere to this guidance and 
the associated legislative requirements. They 
and their supervising pharmacists must ensure 
that there are adequate procedures in place 
in the retail pharmacy business(es) to ensure 
compliance with all of these policies.
• The pharmacist should ensure that suitable 
controls and accountability mechanisms 
are in place to govern the management of 
the supply and distribution of medicinal 
products which have the potential for abuse 
or dependency.
• A pharmacy-specific policy addressing the 
supply of medicines containing codeine 
should be developed, with specific patient 
consultation protocols included. All 
pharmacy staff should be familiar with these 
policies and should be trained in associated 
procedures.
• In any retail pharmacy business supplying 
codeine medicines, it is the responsibility 
of the superintendent pharmacist to 
ensure there is a policy in place to manage 
such supply. It is the responsibility of the 
supervising pharmacist to develop, maintain 
and ensure adherence to this policy and it 
is the responsibility of each pharmacist to 
ensure they and their staff fully comply with 
its provisions.
• These policies and procedures should 
take account of the current legislative 
requirements and the guidance criteria 
included in this document.
 
4.3 Management and 
Supervision of Codeine 
Medicines (CD5 medicines)
According to the Regulation of Retail Pharmacy 
Businesses Regulations 2008 (S.I. No. 488 of 
2008), any medicinal product containing a 
prescription-only medicine or a CD5 medicine 
must not be accessible to the public for self-
selection. Therefore, codeine medicines must 
be in an area of the retail pharmacy business 
under the pharmacist’s direct management 
and supervision, out of the sight of the public. 
The recommended location is in the dispensary 
unless, for justifiable reasons, e.g. a shortage 
of storage space, an alternative out-of-sight 
location within the pharmacy is used. This area 
must be close to the dispensary and therefore 
under the pharmacist’s direct supervision.
 
4.4 Suspected Abuse and/or 
Misuse
If a pharmacist becomes aware of a suspected 
abuse/misuse/addiction issue regarding a 
specific patient and directly associated with the 
use of codeine medicines, they should make all 
reasonable attempts to ensure that the patient 
is facilitated and encouraged in accessing 
services which will assist in the management 
of that addiction. The patient should be 
referred in the first instance to their general 
practitioner or an addiction outreach worker, 
if available in the area. Further information on 
the available services can be obtained from the 
HSE website, www.hse.ie.
The policy and procedures documentation in 
the retail pharmacy business should include 
contact details for the national and/or local 
support and treatment services which are 
available to patients.
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In order to ascertain whether abuse and/or 
misuse is occurring, pharmacists will need 
to monitor or audit the sale and supply of 
these medicines on an ongoing basis. The 
management of any data or information 
recorded, collected or retained as part of this 
monitoring or audit should be in accordance 
with relevant legislative provisions, including 
the relevant Data Protection legislation.
 
4.5 Pharmacovigilance
As with all medicines, any suspected adverse 
reaction should be reported to the Health 
Products Regulatory Authority (HPRA), 
preferably online, via the HPRA website,  
www.hpra.ie.
 
4.6 Advertising of Codeine 
Medicines
The advertising of codeine medicines is 
prohibited. This would include any form of 
window displays, in-pharmacy promotions  
and promotional displays, promotional leaflets 
and shelf stickers.
 Version Number Date Issued
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5. Self-assessment Checklist 
This self-assessment checklist is a practical tool intended to aid compliance with this guidance and 
to assist superintendent and supervising pharmacists in drawing up the relevant policies and SOPs. 
The checklist captures many important elements of the guidance; it is not exhaustive and should 
only be used to assess pharmacy practice in combination with this guidance and all other relevant 
guidance and requirements.
Ask Yourself Yes No N/A Required Action
Are all staff members aware of the indications for 
codeine containing products and that non-codeine 
containing products for the same indication should be 
considered as first line treatment?
Are codeine medicines only supplied by or under the 
personal supervision of a pharmacist?
If supply is appropriate, is the importance of adhering 
to the recommended dosage and duration of use 
highlighted during each consultation?
Are patients appropriately counselled on the side effects 
of these medicines, as well as the risks associated with 
overdose and/or prolonged use?
Are codeine medicines stored out of sight of the public 
in an area of the pharmacy which is not accessible to the 
public for self-selection?
Does the pharmacist monitor/audit the use of these 
medicines in order to establish potential patterns of 
abuse/misuse?
Are there written policies and procedures in place for all 
aspects of the supply of medicines containing codeine? 
Is the superintendent pharmacist and supervising 
pharmacist satisfied that all pharmacists practising in 
the pharmacy, and relevant staff members, are trained 
on, and following, the policies and procedures?
